BAX

Analyzing the Decline in BAX Stock Prices

This morning we watched Baxter International drop -8.4% to a price of $36.95 per share. The Large-Cap Medical Instruments & Supplies company is now trading -17.9% below its average target price of $45.0. Analysts have set target prices ranging from $39.0 to $54.0 per share for Baxter International, and have given the stock an average rating of hold.

The stock has an average amount of shares sold short at 2.5%, and a short ratio of 2.84. The company's insiders own 0.37% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 92.6% of Baxter International's shares being owned by this investor type.

Institutions Invested in Baxter International

Date Reported Holder Percentage Shares Value
2023-12-31 Vanguard Group Inc 12% 60,155,132 $2,222,431,333
2023-12-31 Blackrock Inc. 12% 59,679,868 $2,204,872,705
2023-12-31 Dodge & Cox Inc 5% 27,381,465 $1,011,608,216
2023-12-31 Pzena Investment Management Llc 5% 24,270,170 $896,661,423
2023-12-31 State Street Corporation 4% 21,355,874 $788,992,758
2023-12-31 Price (T.Rowe) Associates Inc 3% 16,398,589 $605,845,865
2023-12-31 JP Morgan Chase & Company 2% 12,304,029 $454,572,347
2023-12-31 Ameriprise Financial, Inc. 2% 11,156,422 $412,174,007
2023-12-31 Geode Capital Management, LLC 2% 11,087,669 $409,633,927
2023-12-31 Harris Associates L.P. 2% 9,254,946 $341,923,977

Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Baxter International.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS